Apoptotic hepatocytes release factors that activate Hepatic Stellate Cells (HSCs) thereby inducing hepatic fibrosis. In the present study, in vivo and in vitro injury models were established using acetaminophen, ethanol, carbon tetrachloride or thioacetamide. Hepatotoxicant-induced diseased hepatic tissue histology correlated with a differential expression of fibrosis-related genes. Marked increase in co-staining of TGFRIIβ-Desmin or α-SMA-PDGFRβ, markers of activated HSCs, in liver sections of these hepatotoxicant-treated mice also depicted an increase in Annexin V-Cytokeratin expressing hepatocytes. To understand the molecular mechanisms of disease pathology, in vitro experiments were designed using the conditioned medium (CM) of hepatotoxicant treated HepG2 cells supplemented to HSCs. Significant increase in HSC proliferation, migration and expression of fibrosis-related genes and protein were observed thereby suggesting the characteristics of an activated phenotype. HepG2 cells when treated with hepatotoxicants resulted in significant increase in mRNA expression of PDGF-BB and TGFβ and its CM when treated to HSCs resulted in increased phosphorylation of PDGFRβ and TGFRIIβ along with its downstream effectors, ERK1/2 and FAK. Neutralizing antibodies against PDGF-BB and TGFβ effectively perturbed the hepatotoxicant-treated HepG2 cells CM-induced activation of HSCs. This study suggests PDGF-BB and TGFβ as potential molecular targets for developing anti-fibrotic therapeutics.
D r a f t D r a f t D r a f t Introduction Liver disease-related mortality rates are a serious health burden that is increasing worldwide.
Nonalcoholic fatty liver disease (NAFLD) has been observed to be the major cause of liver diseases in the recent years (Tarantino and Caputi 2011) . NAFLD includes comorbidities such as cardiovascular risks that increase the rate of mortality in patients. Incidentally, drug induced liver injury (DILI) has also been observed in patients with rampant use of natural products such as herbal or dietary supplements, prescribed medications and other drugs that result in liver fibrosis thereby posing hindrances in the drug discovery, development and clinical care (Tarantino et al. 2009 ). Liver fibrosis is the final common pathway observed in various liver diseases (Melato et al. 2006; Asrani et al. 2013; Qua et al. 2011) with increased synthesis and production of extracellular matrix components. The end stage of fibrosis leads to cirrhosis wherein the liver becomes hardened and completely non-functional. Recently several studies have refined the knowledge about various types of liver diseases, but efficacious therapeutics are still lacking.
Therefore, it becomes pertinent to understand the molecular signaling mechanisms involved in progression of disease to successfully treat the ailment.
The different stages of liver disease comprises of inflammation, fibrosis and cirrhosis that includes specific hepatic cellular milieu -hepatocytes, hepatic stellate cells (HSCs), sinusoidal endothelial cells, kupffer cells and cholangiocytes. Hepatocytes comprising about 70-85% of liver mass, are prone to primary attack of hepatotoxicants. Acute injury-mediated damage caused to hepatocytes often reverts back to normal conditions due to regenerative capacity of hepatocytes. However, continuous insult by hepatotoxicants results in chronic injury with apoptosis of hepatocytes, thereby leading to decreased functional activity of the liver (Gu et al. 2013) . It was hypothesized that these apoptotic hepatocytes express and release several factors D r a f t 4 that results in trans-differentiation of HSCs into activated phenotype with increased proliferative and migratory potential and synthesis of collagen. Thus to identify the factors mediating cellular interactions during injury, in vitro mechanistic studies mimicking the in vivo conditions are necessary. To decipher the disease mechanism, HepG2 cells were exposed to various hepatotoxicants. The use of HepG2 cells instead of primary hepatocytes is a limitation of the present study designed to decipher the molecular mechanisms of pathological events. HepG2 cells, the human hepatoma cell lines are widely used in in vitro studies related to drug toxicity, liver function and metabolism that possess biochemical, morphological similarity with normal hepatocytes. In addition, these cell lines are advantageous for its ease of maintenance for higher passage numbers with no loss of drug metabolizing enzyme activities as encountered with primary cells of hepatocytes (González et al. 2017) . Recent studies have depicted a role of TGFα (Kato et al.2003) as well as HMGB1 (Seo et al. 2013 ) protein in conditioned media (CM) of ethanol treated hepatocytes that lead to the activation of HSCs. Neutralizing antibody against TGF-α and HMGB1 could abrogate the increased collagen mRNA expression/activity and increased migration, respectively in HSCs. Similarly, angiogenin another factor in HepG2 cultured media was observed to activate primary HSCs with higher expression of TGFβ, col1α1 and α-SMA mRNA and protein expressions (Barcena et al. 2015) . Our prior studies depicted the mechanistic role of PDGF-BB and TGFβ in the activation of HSCs by interacting with their cognate receptors or co-receptors and induction of downstream effectors leading to hepatic fibrosis (Brenner al. 2008; Cao et al.2010) . Thus in the present study we identified signaling cross-talk between the apoptotic HepG2 cells and activated HSCs in acute as well as chronic injury conditions that is mediated by PDGF-BB and TGFβ, thereby suggesting these key intermediate molecules as plausible molecular therapeutic targets for liver fibrosis.
D r a f t
Materials and methods
Bio-chemicals and antibodies: Bio-chemicals like acetaminophen (Alfa Aesar, Hyderabad); ethanol, carbon tetrachloride (HiMedia, India); thioacetamide, alanine, aspartic acid, αketoglutaric acid, dinitro phenyl hydrazine, NaOH, 1% chloramine-T, perchloric acid, dimethyl amino benzaldehyde, haematoxylin, eosin, Sirius red, DPX mounting medium, dihydroethidium, thiobarbituric acid reagent, trizol reagent, MTT, 2',7' -dichlorofluorescin diacetate stain, paraformaldehyde, triton X-100 (Sigma, USA); hoechst stain (Molecular Probes, USA); complementary DNA synthesis kit and SyBr Green (Takara, Japan); DAB IHC staining kit (Invitrogen, USA), Annexin V FITC stain kit (Biolegend, USA); HEMA 3 stain kit (Fisher Scientific, USA); PDGF-BB and TGF-1β (Gibco, USA) were of analytical grade.
Antibodies against Annexin V, α-SMA, PDGFRβ, ERK1/2 (Thermo Scientific, USA); FAK (Cell Signaling Technologies, USA) and TGFRIIβ and β-tubulin (Abcam, USA) were used in this study.
In vivo liver fibrosis models: For the in vivo liver fibrosis experiments, 3-4 months old of either sex C57BL/6J mice were maintained under conditions approved by institutional animal ethical committee in accordance to the "Guide for the Care and Use of Laboratory Animals". Acute liver injury was established using acetaminophen (AAP) at a concentration of 300mg/kg body weight as described earlier (Sullivan et al. 2012) . Briefly, mice were pre-starved for a period of 16 h and acetaminophen was administered intraperitoneally (ip.) for once. 24 h after the treatment mice were euthanized and liver tissues were harvested for biochemical, histological and molecular analysis. Chronic liver fibrosis was established by oral administration of 50% ethanol (EtOH;
D r a f t 6 administered i.p at a dose of 0.5mg/kg body weight (Resa et al. 2013 ) for a period of 6 weeks (thrice a week). Similarly, another chronic chemical-induced liver injury model was established using thioacetamide (TAA) administered i.p at a dose of 300mg/kg body weight for a period of 6 weeks thrice a week (Kilment et al. 2011) . With the completion of the hepatotoxicant treatment, the mice were euthanized and tissues were harvested and processed as described below.
Histology studies: Histological changes of liver tissue both in control and toxicant treated mice were estimated using haematoxylin and eosin staining (H&E) and sirius red staining. The liver sections were hydrated in PBS followed by serial incubation with H&E or sirius red stain as described earlier. The excess stain was destained using 90% alcohol, followed by clearing using xylene and mounting the slides with DPX mounting medium.
Determination of oxidative stress:
Dihydroethidium (DHE) staining: Oxidative stress induced generation of reactive oxygen radicals were identified using DHE staining. Liver tissue sections were incubated with 10µm DHE solution in dark for 15 min. This is followed by washing the excess stain and then imaging with fluorescence microscope under red filter at 20× (Olympus, Japan).
Biochemical estimation of malondialdehyde content by TBARS assay: Malondialdehyde (MDA) content in control and diseased livers were measured using TBARS (thio barbituric acid reactive substances) assay. Briefly, homogenized liver tissue was centrifuged to collect the pellet. 10% trichloro acetic acid was added to the pellet and re-centrifuged to collect the supernatant, followed by addition of 0.67% thiobarbituric acid. The reaction mixture was then incubated at 90 ͦ C for 30 min thereby measuring the absorbance at 532nm. Changes in the molecular gene expression levels: The molecular changes in levels of gene expression in control and hepatotoxicants treated mice were estimated using quantitative realtime polymerase chain reaction (qRT-PCR). Briefly, RNA was isolated from mice liver tissues using trizol reagent and its complementary DNA (cDNA) was synthesized, followed by quantitative PCR using step one plus software, of various fibrotic genes using species-specific primers as listed in Table S1 . The Ct values obtained were normalized against β-actin housekeeping gene and data was represented in the form of fold change.
Generation of heat map: Heat map of the gene expression levels was generated in all liver fibrosis models utilizing Gitools software (Perez et al. 2011) . The fold change values obtained through qRT-PCR were loaded in the software to visualize heat map representing variations in the level of gene expression.
Protein expression studies using immunofluorescence: Liver tissue sections were stained with TGFRIIβ, Desmin, α-SMA, PDGFRβ, Cytokeratin 18 and/or Annexin V according to the manufacturer's protocol. Briefly, liver tissues were processed through cryotome sectioning and sections were fixed on slides, followed by hydration with PBS. Later, the tissues were blocked using 1% BSA, followed by primary antibody incubation overnight in a humid chamber box.
Further, the liver sections were incubated with secondary antibody labeled with fluorophores for 1 h, followed by PBS washing and mounting using DPX mounting media. The slides were then imaged at 10× under confocal (FV10i ,Olympus, Canada) microscopy.
In vitro liver injury models:
Cell Culture: HepG2 cell lines (ATCC, USA) were cultured in Dulbecco's modified eagle's medium supplemented with 1% antibiotic solution (Penicillin streptomycin) and 10% fetal D r a f t 8 bovine serum (FBS) and HSCs (ScienCell, USA) were cultured in stellate cell-specific media supplemented with growth factors, 10% FBS and 1% antibiotic solution (Lonza, USA). Cells were cultured in a sterile incubator maintaining 37 o C with 5% CO 2 .
Cell proliferation assay-MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) :
The cell viability was assessed by MTT assay wherein the active NADPH enzyme reduces the tetrazolium dye to its insoluble formazan crystals that can be solubilized with DMSO. Briefly, HepG2 cells were seeded in a 96 well plate at a concentration of 5 × 10 3 cells/well. After 24 h cells were treated with increasing concentrations of hepatotoxicants -AAP (10 -30mM) or EtOH (25 -100mM) or CCl 4 (0.1 -1.0%) or TAA (500-1000µg/mL) for 24 h followed by evaluation of their proliferative potential using MTT (Barapatre et al. 2016 ) while the hepatotoxicants treated HepG2 CM were collected and treated to HSCs for further 24 h and subjected to evaluation of HSC proliferation using MTT assay.
Apoptosis assays:
Hoechst 3342 staining: HepG2 cellular apoptosis-induced nuclear condensation and DNA fragmentation was identified using Hoechst 3342 staining. HepG2 cells were treated with hepatoxicants for 24 h as described above. Briefly, the cells were treated with 1mg/mL of Hoechst dye for 30 min in dark. Cell imaging was performed under fluorescence (IX71, Olympus, Japan) microscopy at 20× (Shareef et al. 2015) .
Annexin V-FITC/PI staining: Separately, another assay was performed to detect apoptosis of HepG2 cells under similar treatments using Annexin V FITC/PI staining according to the D r a f t 9 manufacturer's protocol and analyzed using flow cytometry (Amnis Millipore, USA) (Geesala et al. 2017) .
Immunoblot analysis: HepG2 cells were treated with either 30mM AAP or 75mM EtOH or 1% CCl 4 or 750µg/mL TAA for 24 h. The extracted protein lysates were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene difluoride (PVDF) membrane followed by immunobloting with annexin V antibody and detected using chemiluminiscence reagent (Merck Millipore, USA) (Manupati at al. 2017) .
Measurement of intracellular ROS:
Intracellular ROS levels were measured using DHE staining and dichlorofluorescein diacetate (DCFDA) assay.
DHE staining: HepG2 cells were plated in 6-well plates with coverslips (5 × 10 4 cells/well) and treated with various concentrations of hepatotoxicants (AAP-30mM; EtOH-75mM; CCl 4 -1%; -TAA-750µg/mL) for 24 h. After incubation, the cover slips containing HepG2 cells were stained with DHE as discussed earlier (Haddad et al. 2011 ).
DCFDA staining: HepG2 cells were plated in 96-well plate and treated with hepatotoxicants for 24 h as described above followed by incubation with DCFDA (10µM) for 45 min and evaluation under fluorescence reader with excitation and emission spectra at 485 and 535 nm, respectively (Haddad et al. 2011) .
Biochemical analysis of secreted enzymes: HepG2 cells were treated with hepatotoxicants for 24
h and the CM was collected and evaluated for biochemical activities of secreted enzymes -D r a f t 10 AST/ALT as described earlier (Kim et al. 2008) . To the 100µl of substrate (AST/ALT) buffer, 20 µl of sample was added and incubated at 37 o C for 5 min. This was followed by addition of dinitro phenyl hydrazine, incubating at room temperature for 20 min and addition of NaOH. The reaction mixture was thoroughly mixed and measured at 520 nm.
Gene expression analysis:
HepG2 cells were treated with hepatotoxicants for 24 h and mRNA expression of PDGF-B, PDGF-C, PDGF-D, CTGF, TNF-α or TGFβ were analyzed using qRT-PCR as described earlier.
Molecular analysis of HSC activation:
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR): HSCs were cultured with CM of HepG2-treated hepatotoxicants for 24 h. Total RNA isolated was used for cDNA synthesis followed by qRT-PCR to analyze the expression of fibrotic markers (Resa et al. 2013 ).
Immunoblot analysis: PDGF-BB or TGFβ (10ng/mL) or CM of hepatotoxicant-treated HepG2 cells were treated to HSCs, protein lysates were resolved as described above and probed with antibodies against phosphorylated and total PDGFRβ, TGFRIIβ, FAK, and ERK1/2 as well as βtubulin antibody as loading control (Manupati et al. 2017) .
Immunostaining analysis: HSCs were seeded in 6-well plates with coverslips at a concentration of 5 × 10 4 cells/well and cultured with CM of HepG2-treated hepatotoxicants, followed by fixation with 4% paraformaldehyde and permeabilization with 0.2% Triton X-100. Cells were 
Functional analysis of HSC activation:
Cell proliferation assay: HSCs proliferation was determined in presence of recombinant PDGF-BB or recombinant TGFβ (10ng/mL) or separately in presence of hepatotoxicants-treated HepG2 CM with/without PDGF-BB / TGFβ neutralizing antibodies using MTT assay as mentioned above (Barapatre et al. 2016) .
Cell migration assay-Chemotaxis: PDGF-BB or TGFβ (10ng/mL) or separately hepatotoxicanttreated HepG2 CM, with/without PDGF-BB / TGFβ neutralizing antibodies was added into lower wells along with HSCs plated onto upper wells of the Boyden chamber and incubated at 37 ͦ C for 4 h. Post-incubation the membrane was stained with HEMA-3 stain kit and the number of cells migrated were calculated as described earlier (Seo et al. 2013 ).
Statistical analysis:
All the results were expressed as Mean ± standard deviation (SD). To determine the difference between treatment group and their respective controls, Graph Pad prism version 6.05 was used for analyzing statistical significance (P≤0.05) using one-or two-way ANOVA followed by Tukey's multiple comparison test. Blots and photomicrographs represent experiments reproduced at least thrice with similar results.
Results:
Liver is a unique organ with the ability to regenerate. However, an acute or chronic exposure of various hepatotoxicants affects the regenerative capacity of liver and often results in significant increase in the liver weight. Since the ratio of liver weight to body weight is an index to determine hepatic damage, analysis of the same depicted significant increase in organ weight to D r a f t body weight with chronic hepatotoxicants treatment EtOH, CCl 4 and TAA (Table 1) 
Fibrosis-related gene expression:
Next we set out to understand the molecular gene level alterations induced through different hepatotoxicants by determining the mRNA expression profile of various fibrosis markers. Activated HSCs marker, α-SMA was significantly upregulated in CCl 4 ( Fig 1C) and TAA ( Fig 1D) -treated chronic injury models whereas its level remained unchanged in AAP-induced ( Fig 1A) and ethanol-treated ( Fig 1B) mouse model of liver injury. This suggests a gradual increase in transdifferentiation of HSCs into myofibroblastlike cells that is known to secrete ECM proteins such as collagen, fibronectin, etc. with the progression of disease. Gene expression analysis of an ECM component collagen1α1 gene revealed a 4 -fold higher in EtOH, (Fig 1B) and CCl 4 ( Fig 1C) -treated injury models whereas in AAP ( Fig 1A) and TAA ( Fig 1D) -treated models its expression remained unchanged.
D r a f t Interestingly, fibronectin, another ECM component was observed to be significantly up-regulated in both acute and chronic injury models generated using different hepatotoxicants.
Growth factors such as TGF and PDGF play a critical role in liver diseases. The mRNA expression levels of these growth factors depicted a significant increase along with their cognate receptors TGFRIIβ and PDGFRβ in both AAP ( Fig 1A) and TAA ( Fig 1D) -treated injury models. Interestingly, EtOH ( Fig 1B) and CCl 4 ( Fig 1C) -induced injury models depicted a significant increase in expression of only TGF-1β/TGFRIIβ or PDGF-BB/PDGFRβ, respectively. This data suggests that ethanol and CCl 4 treatment leads to hepatic fibrosis via activation of differential molecular mechanisms.
Next we studied matrix metalloproteinases (MMPs) that are known to degrade the ECM components during fibrosis to maintain the homeostasis within the hepatic tissue. Among the various MMPs evaluated, we observed a differential mRNA expression in these liver injury models. AAP ( Fig 1E) and CCl 4 ( Fig 1G) -treated injury models depicted a significant increase in expression of MMP2, MMP9 and MMP13, whereas only MMP13 was significantly upregulated in TAA -treated mice ( Fig 1H) . In EtOH -treated mice the mRNA expression of these MMPs did not depict any significant change as compared to its control ( Fig 1F) . These findings suggest that MMPs-mediated ECM remodeling occurs in both acute (AAP) and chronic (CCl 4 and TAA) -injury models with an exception in EtOH -treated chronic injury model.
Further we analyzed the mRNA expression levels of few other liver disease-specific markers like dipeptidyl peptidase-4 (DPP4), hepatocyte necrosis factor (HNF-α), growth arrest specific gene 6 (Gas-6) and tumor necrosis factor (TNF-α). HNF-α, a transcription factor that plays a crucial role towards hepatocyte functions and TNF-α, an inflammatory marker were up-regulated with AAP D r a f t ( Fig 1E) ; CCl 4 ( Fig 1G) ; whereas only HNF-α was increased with EtOH ( Fig 1F) and TAA ( Fig   1H) treatment to mice. DPP4, a serine protease; associated with liver disease and Gas-6, expressed by various hepatic cells including Kupffer cells were highly up-regulated with AAP ( Fig 1E) ; EtOH ( Fig 1F) ; TAA ( Fig 1H) but not with CCl 4 (Fig 1G) . Additionally, liver endothelial cell markers, platelet endothelial cell adhesion molecule (PECAM) and von Willebrand factor (vWF) were significantly up-regulated with AAP ( Fig 1E) and EtOH ( Fig 1F) whereas CCl 4 treatment to mice affected neither of them ( Fig 1G) and TAA treatment increased the mRNA expression of only PECAM (Fig 1H) . Based on qRT-PCR analysis a heat map was generated to represent the expression profile of various fibrosis genes. With acute injury caused by AAP treatment, most of the fibrosis-related genes were expressed in the range of moderate to high levels (Fig 1I) , while EtOH and CCl 4 treatments, resulted in lower to moderate levels of fibrosis genes ( Fig 1I) . In addition, TAA-induced chronic liver injury in mice resulted in moderate to higher levels of most of the fibrosis genes ( Fig 1I) . This differential transcriptomic profile in liver injury models suggested that although different hepatotoxicants can lead to liver fibrosis but there exist different molecular targets.
Protein expression studies: To correlate the higher mRNA expression of PDGFRβ and TGFRIIβ, protein expressions were also evaluated. Results depicted markedly high co-localization of TGFRIIβ/Desmin (Fig 2A) and α-SMA/PDGFRβ (Fig 2B) in the liver sections of hepatotoxicant treated chronic injury mice as compared to vehicle control. This observation suggests that hepatotoxicant-treatment resulted in activation of PDGFRβ and TGFRIIβ expressing HSCs. Activated HSCs are known to express α-SMA and Desmin. Since treatment with hepatotoxicants can lead to apoptosis of hepatocytes, we analyzed the co-localization of Annexin V/Cytokeratin D r a f t from acute to chronic treatments of hepatotoxicants, led to a markedly high apoptosis of hepatocytes ( Fig 2C) . Interestingly, tissue polypeptide specific antigen, a serological mirror of Cytokeratin 18 expressed by apoptotic hepatocytes has been recently considered as a marker for clinical diagnosis between different types of liver diseases such as fatty liver and nonalcoholic steatohepatitis (Tarantino et al. 2007 ).
Generation of oxidative stress due to hepatotoxicants: Hepatotoxicant induced generation of reactive oxygen intermediates are known to be associated with progression of the disease. To evaluate the Reactive Oxygen Species (ROS) generated due to these treatments, DHE staining was performed as described in the methods. DHE staining was higher in AAP ( Fig S2A) treated mice when compared to its respective control. Similar findings were noticed with EtOH ( Fig   S2B) ; CCl 4 ( Fig S2C) ; TAA ( Fig S2D) liver injury models. These observations indicated differential levels of oxidative stress with diverse toxicants-induced development of liver disease.
Oxidative stress induced lipid peroxidation due to hepatotoxicants: Further to analyze oxidative stress induced lipid peroxidation, we performed TBARS assay that measures the MDA content.
Our results displayed significant increase in MDA content as compared to respective control with chemical induced liver injuries-CCl 4 ( Fig S2G) and TAA ( Fig S2H) . Surprisingly, AAP ( Fig   S2E) and EtOH ( Fig S2F) did not alter the MDA content. Thus, these results suggests that although a differential levels of oxidative stress was generated due to hepatotoxicant treatment lipid peroxidation was significantly evident in chronic injury models of liver injury only.
Hepatotoxicant-induced apoptosis of HepG2 cells:
In order to identify the plausible cellular interactions that takes place during hepatotoxicant-induced liver injury conditions, in vitro liver D r a f t injury models were established using AAP (1-30mM), EtOH (25-100mM), CCl 4 (0.1-1.0%) or TAA (500-1000µg/mL). HepG2 cells, a human hepatoma cell line were utilized for evaluating the in vitro mechanistic studies. HepG2 cells depicted a dose-dependent decrease in proliferation in presence of hepatotoxicants -AAP ( Fig 3A) , EtOH (Fig 3B) , CCl 4 ( Fig 3C) and TAA ( Fig   3D) . To identify whether decrease in HepG2 proliferation was due to apoptosis of cells, hoechst staining was performed in HepG2 cells treated with AAP, EtOH, CCl 4 and TAA at the maximal concentration of decreased cell proliferation. We observed markedly high nuclear DNA fragmentation in hepatotoxicant-treated groups indicating the apoptosis of cells ( Fig 3E) . These results were further substantiated by the flow cytometric analysis using annexin V/PI staining.
Indeed, AAP and EtOH treatments resulted in higher ~35% and ~24% of cells, respectively in late apoptotic stages (Fig 3F, upper panel) while CCl 4 treatment led to a markedly high percentage of cells (~80%) undergoing early apoptosis as well as ~8.5% of cells undergoing late apoptosis ( Fig 3E, lower panel) . Similarly, TAA treatment also led to ~60% of cells in early apoptosis while ~8.1% cells in late apoptotic stage. Additionally, at a molecular level, there was higher annexin V protein expression in hepatotoxicant-treated HepG2 cells as compared to control ( Fig 3G) . These results together indicate that HepG2 cells undergo apoptosis in presence of hepatotoxicants at a cytotoxic concentration.
Hepatotoxicant-induced oxidative stress in HepG2 cells: Analysis of the level of oxidative stress
in HepG2 cells undergoing hepatotoxicant-induced apoptosis, depicted a marked increase in intracellular ROS levels (DHE staining) in HepG2 cells treated with 30mM AAP or 75mM EtOH or 1% CCl 4 or 750µg/mL TAA as compared to control ( Fig 3H) . This data was further substantiated with similar observations using DCFDA staining of HepG2 cells treated with D r a f t 30mM AAP, 1% CCl 4 or 750µg/mL TAA but not EtOH as compared to untreated control cells ( Fig 3I) . Due to disease progression, hepatic cells undergoing apoptosis experience membrane damage leading to release of elevated levels of hepatic enzymes into the microenvironment. Therefore, we estimated AST/ALT enzyme activities in the conditioned media (CM) of hepatotoxicants-treated HepG2 cells. A significant increase in AST ( Fig 3J) but not ALT ( Fig   3K) enzyme activity was observed in HepG2 cells treated with CCl 4 , AAP or EtOH as compared to control while TAA did not alter either of the cellular enzyme activities.
Conditioned medium of hepatotoxicant-treated HepG2 cells led to activation of HSCs:
HSCs are considered to be important collagen producing cells that undergo activation and play a key role in fibrosis during disease progression (Kato et al. 2003) . To evaluate if apoptotic hepatocytes release factors that lead to activation of HSC, we cultured HSCs with CM of hepatotoxicanttreated HepG2 cells as described in the methods. Interestingly, CM of hepatotoxicant-treated HepG2 cells led to significant increase in proliferation ( Fig 4A) and migration ( Fig 4B) of HSCs, characteristic hallmarks of an activated HSC phenotype. Next, we observed a marked increase in the protein expression of α-SMA in these activated HSCs (Fig 4C) . In order to identify the nature of released factors from HepG2 cells that result in activation of HSCs, CM was differentially treated -serum free conditions, boiling (90˚C, 30 min), and proteinase K digestion (200µg/mL, 37˚C, 1 h) before treating HSCs. CM of 75mM EtOH or 30mM AAP or 750µg/mL TAAtreated HepG2 under serum free conditions led to significantly less proliferation of HSCs as compared to control ( Fig 4D) . Interestingly, CM of 1% CCl 4 under serum free conditions did not differ than the serum containing conditions on the proliferation of HSCs (Fig 4D) . Boiling of the CM led to significant decrease in proliferation of HSCs in presence of CM of HepG2 cells D r a f t treated with 1% CCl 4 or 750µg/mL TAA -treated group but not in 75mM EtOH or 30mM AAPtreated group (Fig 4D) . Proteinase K digestion of the CM successfully down-regulated HepG2treated hepatotoxicants CM-induced HSC proliferation in all the treatment groups thereby suggesting a plausible role of proteins secreted by HepG2 cells in the CM that might be activating the HSCs.
In the pursuit of identifying the factors released by hepatocytes that activate HSCs, based on our prior studies (Barcena et al. 2015; Brenner et al. 2008) as well as others (Friedman 2008 ) a plausible role of growth factors such as CTGF, PDGF-BB, PDGF-C, PDGF-D, TNF-α and TGFβ were evaluated (Fig 4E and S3 ). HepG2 cells treated with these hepatotoxicants depicted a significant increase in mRNA expression of PDGF-BB and TGFβ as compared to control ( Fig   4E) whereas other growth factors such as CTGF, TNFα, PDGF-C and PDGF-D were not the altered in presence of all the studied hepatotoxicants ( Fig S3) , thereby suggesting a possible role of PDGF-BB and TGFβ being released by HepG2 cells that activates HSCs.
PDGF-BB or TGFβ mediated activation of HSCs:
In our present study, we observed a significant D r a f t
PDGF-BB and TGFβ-mediated expression of fibrosis-related genes in activated HSCs:
To elucidate the molecular gene expression level alterations in presence of hepatotoxicants-treated HepG2 cells CM, qRT-PCR was performed. Expression of fibrotic genes like α-SMA, Col1α1
and TGF1β were significantly up-regulated in activated HSCs supplemented with 30mM AAP (Fig 5D) , 75mM EtOH (Fig 5E) , 1% CCl 4 (Fig 5F) hepatotoxicants -treated HepG2 cells CM.
Interestingly, a significant increase in mRNA expression of PDGFRβ was observed in HSCs supplemented with hepatotoxicant-treated HepG2 CM (Fig 5D-G) that was reverted in presence of PDGF-BB neutralizing antibody. However, TGFRIIβ mRNA expression in HSCs was increased only in presence of AAP ( Fig 5D) or CCl 4 ( Fig 5F) -treated HepG2 CM. Among the MMPs and its tissue inhibitor of matrix metalloproteinases (TIMPs), a differential expression profile was observed in the activated HSCs. In presence of 30mM AAP or 75mM EtOH -treated HepG2 CM to HSCs, significant increase in MMP2, MMP7, MMP13 was observed along with a difference in expression of TIMP1 in the former ( Fig S4A) and TIMP2 in the latter (Fig S4B) .
However, in the presence of 1% CCl 4 -treated HepG2 CM, a marked increase in MMP2, MMP9 along with TIMP1 ( Fig S4C) was observed in activated HSCs. In contrast, TAA treated CM did not alter the expression of MMPs but has up-regulated TIMP1 and TIMP2 expression ( Fig S4D) .
Together, these observations identify the lead role of PDGF-BB and TGFβ present in CM that bind to their cognate receptors -PDGFRβ and TGFRIIβ, respectively expressed on the HSC and activates them.
PDGF-BB and TGFβ-neutralization in CM reverted back the activation of downstream signaling
in HSCs: Next we evaluated the hepatotoxicant-mediated activation of p-TGFRIIβ, p-PDGFRβ along with its downstream effectors p-ERK1/2 and p-FAK in presence of neutralizing antibodies.
D r a f t 20 Either TGFβ or PDGF-BB neutralizing antibody could markedly down-regulate 1% CCl 4 induced phosphorylation of TGFRIIβ and PDGFRβ in HSCs ( Fig 5H) . Interestingly, hepatotoxicant-induced activation of FAK, a non-receptor tyrosine kinase that plays an important role in migration, was markedly decreased in presence of both TGFβ or PDGF-BB neutralizing antibody indicating down-regulation of activated HSC phenotype (Fig 5H) . Similarly, activation of ERK1/2 in presence of hepatotoxicants was also reversed in presence of TGFβ or PDGF-BB neutralizing antibody ( Fig 5H) . Similar observations were also observed in HSCs supplemented with HepG2 -treated 30 mM AAP or 75 mM EtOH CM ( Fig 5H) as well as 750µg/mL TAAtreated HepG2 CM (data not shown). These findings suggest that PDGF-BB and TGFβmediated activation of HSCs occurs through the downstream effectors, ERK1/2 and FAK signaling for proliferation and migration, respectively.
PDGF-BB and TGFβ -neutralization in CM reverted back the functional activation of HSCs:
Hepatotoxicants-treated HepG2 CM-induced significant increase in activation of HSCs was evaluated in presence of PDGF-BB or TGFβ neutralizing antibody. A differential effect of these neutralizing antibodies was observed in AAP or EtOH -treated HepG2 CM-induced HSC proliferation or migration as compared to control or IgG antibody control. Both the PDGF-BB and TGFβ -neutralizing antibodies could significantly decrease the AAP-treated HepG2 CMinduced HSC proliferation ( Fig 6A) whereas the migration was decreased only in presence of the former (Fig 6B) . TGFβ neutralizing antibody could but not PDGF-BB neutralizing antibody inhibit the EtOH-treated HepG2 CM-induced HSC proliferation ( Fig 6C) whereas both the neutralizing antibodies could significantly decrease the migration of HSCs (Fig 6D) . Similarly, PDGF-BB or TGFβ neutralizing antibodies could significantly decrease the 1% CCl 4 or D r a f t 750µg/mL TAA-treated HepG2 CM-induced proliferation (Fig 6E, 6G) and migration (Fig 6F,   6H ) of HSCs. These observations clearly signify the role of PDGF-BB and TGFβ in the activation of HSCs.
Discussion:
In the present study, hepatotoxicant-induced apoptosis of HepG2 cells leading to release of factors that results in activation of resident HSCs was critically explored using cellular interactions between HepG2 cells and HSCs and its downstream signaling response during paracrine factors that are involved in growth, metabolism, immune defense and transport functions of the liver. In addition, the remarkable regenerative capacity of the liver is due to highly proliferative hepatocytes. Due to the significant role of liver in growth and metabolism, alteration in its function affects liver and every other organ of the body leading to ailment. It was observed that hepatocytes are more susceptible to toxic reagents and they undergo apoptosis D r a f t through DNA fragmentation resulting in formation of apoptotic bodies (Sirica et al. 2008) . Major etiologies of liver function damage due to acute viral infection of Hepatitis B Virus or Hepatitis C Virus involves necrosis while chronic injury involves abundant apoptosis and release of cytokines (Abbas et al. 2005 ). In addition, alcohol consumption also stimulates hepatocytes apoptosis through its reactive intermediates acetaldehyde and cytochrome P4502E1 (Wang 2014 (Gong et al. 2017) . Silencing of Prrx1 led to attenuation of TAA-induced liver fibrosis. Studies identified TGF-α as the regenerating cytokine released from damaged hepatocytes during partial hepatectomy (Wang 2014; Gu et al. 2013) , along with its release from hepatocytes treated with EtOH (Brenner et al. 2009 ). In correlation with this identification, we observed the higher mRNA expression of both TGF-1β and PDGF-BB in HepG2 cells treated with AAP, EtOH, CCl 4 and TAA. Furthermore, the activation of HSCs in presence of CM of these hepatotoxicant-treated HepG2 cells was perturbed in presence of PDGF-BB and TGFβ neutralizing antibodies clearly suggests the release of these factors by HepG2 cells. In support to our findings studies have shown that alcohol treated hepatocytes in cell culture studies as well as in human after binge drinking or mice fed with alcohol (at once or chronic) were identified to release exosomes containing miRNA-122. These exosomes were taken up by monocytes thereby inducing hepatic inflammation that was perturbed by using inhibitor/RNA interference against miRNA-122 (Haddad et al. 2011) . These observations add up to the hypothesis for secretory factors released from hepatotoxicant treated hepatocytes that can act as therapeutic targets. Although prior literature suggests that targeting apoptotic hepatocyte using pan-caspase inhibitors decreases the fibrosis but the underlying mechanisms were not evaluated (Brenner et al. 2009) . In this context, this study revealed the signaling crosstalk between apoptotic HepG2 cells and activated HSCs occurs via PDGF-BB and TGFβ. Activation 
